{"schema":"sb.node.v1","id":"sb:e/f7dc83641f938bf3c31f4d81","kind":"entity","label":{"text":"roche","locale":"en"},"identity":{"anchor":"label:en:roche","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-09T23:33:39.923351+00:00","snapshot":"deploy 6f31b5d995496d4885493b8121ab8df3f04643e5"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":156,"separatePublishers":58,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim","receiptsOnTopic":{"state":"measured","share":1,"named":11,"of":11,"basis":"receipts the entity graph keeps whose own headline names the subject, over all receipts it keeps for the subject (the door's measurement; the graph carries none of its own). Only the former are served"}},"admission":{"state":"canonical","reason":"entity graph provenance 'curated'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-06-12","to":"2026-10-08","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.256: about 74% of mentions carry no typed assertion"]}},"dimensions":{"domains":["auto","fda_decisions","biotech_pharma"],"activeDays":35,"assertions":{"regulatory-approval":14,"launch-release":7,"election":5,"utterance":4,"acquisition":4,"military-action":3}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":11,"byKind":{"observation":11},"withheld":{"state":"withheld","count":1,"reason":"1 receipt withheld: no source link (the same rule the topic record applies)"},"items":[{"id":"sb:o/10dfa73582f98ef05bde95ee","kind":"observation","label":"STAT News · 2026-10-08 · STAT+: Roche inks drug discovery deal with Chinese biotech, focused on molecular glue medicines","url":"https://www.statnews.com/2026/10/08/roche-defand-therapeutics-drug-development-deal/?utm_campaign=rss"},{"id":"sb:o/963db2378ab8e771e95ea512","kind":"observation","label":"Endpoints News · 2026-10-08 · Roche does fourth China deal since August, teaming with Defand on degraders","url":"https://endpoints.news/roche-does-fourth-china-deal-since-august-teaming-with-defand-on-degraders/"},{"id":"sb:o/8f6dac0764e6ee31ef089f40","kind":"observation","label":"Fierce Pharma · 2026-10-07 · AbbVie, Genmab score first-line DLBCL win for Epkinly, teeing up challenge to Roche's Polivy","url":"https://www.fiercepharma.com/pharma/abbvie-genmab-tout-ph3-first-line-win-epkinly-mounting-rivalry-roche"},{"id":"sb:o/bf3152d3a320d6ca297b92fb","kind":"observation","label":"Endpoints News · 2026-10-06 · Roche enlists Alector in Parkinson's deal, paying $100M upfront","url":"https://endpoints.news/roche-enlists-alector-in-parkinsons-deal-paying-100m-upfront/"},{"id":"sb:o/1fe097df114b5366d82ab126","kind":"observation","label":"Clinical Trials Arena · 2026-10-02 · EASD 2026: Roche’s enicepatide shows 22.7% placebo-adjusted weight loss at 48 weeks","url":"https://www.clinicaltrialsarena.com/analyst-comment/easd-2026-roches-enicepatide-shows-22-7-placebo-adjusted-weight-loss-at-48-weeks/"},{"id":"sb:o/ca473612dc191700fe98d8a1","kind":"observation","label":"Medical Device Network · 2026-10-01 · Roche’s TIB MOLBIOL introduces in vitro newborn screening test kit","url":"https://www.medicaldevice-network.com/news/roches-tib-molbiol-in-vitro-newborn-test-kit/"},{"id":"sb:o/41683a7847c5c5dd39223c49","kind":"observation","label":"Fierce Biotech · 2026-10-01 · Roche launches simultaneous screening test for SMA, SCID and SCD","url":"https://www.fiercebiotech.com/medtech/roche-launches-simultaneous-screening-test-sma-scid-and-scd"},{"id":"sb:o/959b3af699eb16d07931dfba","kind":"observation","label":"AllSci News · 2026-09-30 · Roche’s fenebrutinib gets FDA priority review for RMS and PPMS","url":"https://allsci.com/news/biotech/fenebrutinib-fda-approval-ms-accepts-roches/"},{"id":"sb:o/0459dff5d747b7b996b125cb","kind":"observation","label":"AllSci News · 2026-09-30 · Chugai resurrects emugrobart in SMA after Roche exits following obesity failure","url":"https://allsci.com/news/biotech/emugrobart-sma-development-chugai-resurrects-for/"},{"id":"sb:o/fc47112865888e54bd63a9cf","kind":"observation","label":"Endpoints News · 2026-09-30 · #EASD26: Zealand and Roche's amylin works best at middle dose, trails Lilly's","url":"https://endpoints.news/easd26-zealand-roches-amylin-works-best-at-middle-dose-but-still-trails-lillys/"}],"cursor":"c1.eyJpZCI6InNiOmUvZjdkYzgzNjQxZjkzOGJmM2MzMWY0ZDgxIiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTA5VDIzOjMzOjM5LjkyMzM1MSswMDowMCJ9","order":"newest first; we keep the 11 newest receipts for this entity whose own headline names it. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":12,"byKind":{"claim":2,"co-mentioned":10},"items":[{"id":"sb:p/446d95a1b34a454b2f8a185c","kind":"claim","label":"AbbVie, Genmab score first-line DLBCL win for Epkinly, teeing up challenge to Roche's Polivy — corroborated","role":"named-in","relationKind":"claim","members":1},{"id":"sb:p/4077eb1421a36ab3ea9ffb4f","kind":"claim","label":"STAT+: Roche inks drug discovery deal with Chinese biotech, focused on molecular glue medicines — single source","role":"named-in","relationKind":"claim","members":1},{"kind":"relation","label":"co-mentioned with fda (51 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/b3bee795e2e1e392ee9cd2ae"},{"kind":"relation","label":"co-mentioned with novartis (43 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/ae48fccd869c932f045589d8"},{"kind":"relation","label":"co-mentioned with astrazeneca (34 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/3ca75e698cdbb9f94aed4ab6"},{"kind":"relation","label":"co-mentioned with studie (34 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/50ca41e323af8c27bf4f20df"},{"kind":"relation","label":"co-mentioned with clinical trials (31 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/d101367a2ed93f7e1304ad77"},{"kind":"relation","label":"co-mentioned with eli lilly (30 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/62ba6d1974bd61ea4a902d01"},{"kind":"relation","label":"co-mentioned with genentech (28 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/e7ff545bba34f893d99fd9d8"},{"kind":"relation","label":"co-mentioned with pfizer (26 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/1cae11a5876246971489e82f"}],"cursor":"c1.eyJpZCI6InNiOmUvZjdkYzgzNjQxZjkzOGJmM2MzMWY0ZDgxIiwibCI6InJlbGF0aW9ucyIsIm8iOjEwLCJrIjpudWxsLCJhIjoiMjAyNi0xMC0wOVQyMzozMzozOS45MjMzNTErMDA6MDAifQ","order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/f7dc83641f938bf3c31f4d81","mcp":"traverse {\"id\":\"sb:e/f7dc83641f938bf3c31f4d81\"}","page":"/entity/roche/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/f7dc83641f938bf3c31f4d81\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/f7dc83641f938bf3c31f4d81\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/f7dc83641f938bf3c31f4d81\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/f7dc83641f938bf3c31f4d81\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}